Program
vemzatatug vedotin
Its studies are mostly in Multiple Myeloma, led by AstraZeneca.
Furthest: phase 2, since Oct 11, 20231 company-led study, 1 open or runningNext primary completion: Jan 24, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Oct 11, 2023 | Oct 11, 2023 | Jan 24, 2028phase 2 · NCT06106945 |
- Named in AstraZeneca’s own pipeline as
AZD0305
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT06106945 · 226 planned · United States, Australia, Brazil and more
- Oct 30, 2026Primary completion moved from 2027-08-16 to 2028-01-24Date moved laterphase 2 · +5 months · NCT06106945
Ahead
- Jan 24, 2028Primary completion: phase 2 study in Multiple MyelomaNCT06106945
TargetBeta
“An antibody-drug conjugate (ADC) composed of vemzatatug, a monoclonal antibody directed against the human G-protein coupled receptor family C group 5 member D (GPRC5D) conjugated to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential…”NCIt, read by Claude
Other programs on GPRC5D
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| arlocabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 3 |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 3 |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 2 |
| MBS314 for Injectionrule | beijing-mabworks-biotech-co-ltd | phase 2 | 1 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-GPRC5D Monoclonal Antibody SAR446523 | Sanofi | phase 1 | 1 |
| tunlucabtagene autoleucel | Bristol-Myers Squibb | phase 1 | 1 |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06106945Multiple Myeloma · United States, Australia, Brazil and more | 2 | Recruiting | Jan 24, 2028 | 226 |
How it is read
Names in the registry
- “AZD0305”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.